A61K 40/4222
Cd38 not igg
Official title: {CD38 not IgG}
A61K40/4222 (Cd38 not igg) appears on 26 US grants and 69 published applications in this corpus.
Search patents in A61K- Granted patents
- 26
- Published applications
- 69
- Assignees
- 45
- Inventors
- 152
- Latest grant
- 7 Apr 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2010 | 0 | 1 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 1 |
| 2017 | 0 | 1 |
| 2018 | 0 | 3 |
| 2019 | 0 | 5 |
| 2020 | 3 | 7 |
| 2021 | 6 | 12 |
| 2022 | 4 | 11 |
| 2023 | 1 | 7 |
| 2024 | 3 | 9 |
| 2025 | 7 | 6 |
| 2026 | 2 | 6 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Multifunctional immunotherapeutic monoclonal antibody complexes and conjugates7 Apr 2026US 12,594,341 B2
- Natural killer cells expressing a chimeric antigen receptor that binds CD3827 Jan 2026US 12,534,536 B2Onk Therapeutics Limited
- Targeting of multiple antigens with multiplex CAR T cells in solid and liquid malignancies11 Nov 2025US 12,466,869 B2Dana-Farber Cancer Institute, Inc.
- Enhanced immune effector cells and use thereof26 Aug 2025US 12,398,373 B2Fate Therapeutics, Inc.
- Compositions and methods for treating cancer with anti-CD38 immunotherapy19 Aug 2025US 12,391,958 B2Lentigen Technology, Inc.
- Compositions and methods for treating cancer with anti-cd38 immunotherapy10 Sep 2026US 2026/0265779 A1Lentigen Technology, Inc.
- Cd38 as integration site for enhanced function of gene-modified immune cells23 Jul 2026US 2026/0207666 A1Research Institute At Nationwide Children's Hospital
- Multifunctional immunotherapeutic monoclonal antibody complexes and conjugates16 Jul 2026US 2026/0199506 A1
- Combined therapies using immunomodulating drugs2 Jul 2026US 2026/0183395 A1Onk Therapeutics Limited
- Activation Inducible Antigen Receptors for Adoptive Immunotherapy25 Jun 2026US 2026/0176369 A1
Most cited
By later US patents
- Chimeric antigen receptors based on single domain antibodies and methods of use thereof17US 10,934,363 B2Legend Biotech USA Inc. · 2021
- Enhanced immune effector cells and use thereof16US 10,927,346 B2Fate Therapeutics, Inc. · 2021
- Enhanced immune effector cells and use thereof10US 11,365,394 B2Fate Therapeutics, Inc. · 2022
- Engineered cells for adoptive cell therapy8US 10,738,278 B2Juno Therapeutics, Inc. · 2020
- Cells for immunotherapy engineered for targeting CD38 antigen and for CD38 gene inactivation5US 10,709,775 B2Cellectis · 2020